58 Notes to Group financial statements 31 DECEMBER 2003 14 FIXED ASSET INVESTMENTS CONTINUED The cost of the investments in the subsidiary undertakings in the books of the Company is as follows: m Cost and net book value at 1 January and 31 December 2003 15.0 B TRADE INVESTMENTS The investments held during 2003 are shares the Group holds in a non-related overseas listed company, Medivir AB.
2003 2002 m m Cost At 1 January and 31 December 1.5 1.5 Amounts provided At 1 January 1.2 1.1 Released provided in the year 0.5 0.1 At 31 December 0.7 1.2 Net book value At 1 January 0.3 0.4 At 31 December 0.8 0.3 The market value of the investment in Medivir AB at 31 December 2003 was 0.8m 2002 0.3m.
C INVESTMENT IN OWN SHARES These are shares in Acambis plc that have been bought by an employee trust.
The shares may be issued to certain employees and Directors as share options or when long-term incentive awards are exercised.
A provision has been made in the financial statements for those shares that are likely to be issued.
Group Company 2003 2002 2003 2002 m m m m Cost At 1 January 1.3 1.6 0.6 0.9 Disposals 0.3 0.3 Transfer from subsidiaries 0.7 At 31 December 1.3 1.3 1.3 0.6 Amounts provided At 1 January 0.5 0.4 0.5 0.4 Provided in the year 0.5 0.4 0.5 0.4 Release of amounts previously provided 0.1 0.3 0.1 0.3 At 31 December 0.9 0.5 0.9 0.5 Net book value At 1 January 0.8 1.2 0.1 0.5 At 31 December 0.4 0.8 0.4 0.1 At 31 December 2003, Acambis Employees Trustees Limited held 582,532 2002 589,685 ordinary shares in the Company with a total market value of 1.8m 2002 1.6m on behalf of the Acambis Employees Trust.
All shares held by the Trust have been allocated to long-term incentive awards and a provision has been made in respect of all of these shares.
All costs relating to the administration of the Trust are dealt with in the accounts of the Company as they arise.
During the year, a provision of 0.5m 2002 0.4m was made in relation to those long-term incentive awards whose performance criteria at 31 December 2003 are expected to be met.
As a result of certain awards being forfeited during the year, there was a release of 0.1m 2002 0.3m, being provisions made in previous years see remuneration report on page 40 for further details.
59 15 ACQUISITION OF SUBSIDIARY In August 2003, the Group acquired BPC a sales, promotion and distribution organisation in North America.
Acambis Inc. acquired 100% of BPCs share capital for 4.0m $6.5m in cash, c. 1.1m $2.0m of deferred consideration and may pay up to an TM additional c. 1.8m $3.2m in milestones from 2004, subject to the achievement of key sales targets for Vivotif and ARILVAX see note 3 below.
The fair value of the assets purchased is set out below: m $m Stock 0.2 0.3 Debtors: amounts receivable within one year 0.1 0.2 Cash at bank and in hand 0.1 0.1 1 Creditors: amounts falling due within one year 0.2 0.3 Net assets acquired 0.2 0.3 Net assets acquired 0.2 0.3 Goodwill arising 6.7 11.4 Purchase consideration 6.9 11.7 Split of consideration: 2 Cash consideration 4.0 6.5 3 Deferred consideration 1.1 2.0 3 Contingent consideration 1.8 3.2 6.9 11.7 NOTES 1 A fair value adjustment was made following acquisition to include an amount within creditors in respect of potential stock returns.
2 The cash consideration includes acquisition expenses of 0.3m.
3 The contingent and the deferred consideration have been discounted to reflect the time value of future payments.
The total potential acquisition cost prior to discounting future cashflows is c. 7.4m $12.5m.
BPC has generated turnover of 0.9m $1.6m and operating profit of 0.2m $0.4m from date of acquisition until 31 December 2003.
16 STOCK Group 2003 2002 m m Raw materials 7.8 1.1 Work in progress 4.1 35.0 Finished goods 6.3 12.3 18.2 48.4 At 31 December 2003 and 31 December 2002, the Company did not hold any stock.
60 Notes to Group financial statements 31 DECEMBER 2003 17 DEBTORS: AMOUNTS RECEIVABLE WITHIN ONE YEAR Group Company 2003 2002 2003 2002 m m m m A Trade debtors 8.9 46.1 Corporation tax 0.2 Other debtors 0.3 2.4 0.6 Prepayments and accrued income 1.0 5.3 Deferred tax asset see note 10 2.1 12.3 54.0 0.6 18 DEBTORS: AMOUNTS RECEIVABLE AFTER ONE YEAR Group Company 2003 2002 2003 2002 m m m m Amounts owed by subsidiary undertakings 28.0 71.6 Prepayments and accrued income 0.1 4.9 0.1 4.9 28.0 71.6 19 CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR Group Company 2003 2002 2003 2002 m m m m Overdraft facility see below 3.9 4.3 B Obligations under finance leases 3.0 Trade creditors 14.5 54.7 0.1 Amounts owed to subsidiary undertakings 13.9 Corporation tax 0.3 0.2 Other taxation and social security 0.4 0.1 Other creditors 0.2 0.1 0.2 C Accruals and deferred income 74.3 29.0 0.5 0.3 Deferred and contingent consideration 0.3 96.9 88.4 14.6 0.4 Under the terms of the agreement between Acambis and Evans Vaccines Limited a subsidiary of Chiron, given certain conditions, the obligation under the bank overdraft facility of 3.9m 2002 4.3m for part of the costs incurred on the TM ARILVAX project may be repayable within one year.
The facility is underwritten by Chiron.
Chiron has granted to Acambis TM 100% of the marketing rights to ARILVAX in the US, whilst retaining an option to buy back 50% of the profits from the US sales TM in return for refunding to Acambis the costs that Acambis has incurred on the ARILVAX programme.
The overdraft facility was renewed in January 2004 for a further year.
Interest is charged as disclosed within Financial liabilities in note 22.
During the year, an exchange gain of 0.4m 2002 0.5m was recorded on the face of the Group profit and loss account, resulting from the revaluation of this US dollar-denominated facility.
20 CREDITORS: AMOUNTS FALLING DUE AFTER ONE YEAR Group Company 2003 2002 2003 2002 m m m m B Obligations under finance leases 9.6 14.0 Accruals and deferred income 0.1 4.9 Deferred and contingent consideration 2.6 12.3 18.9 THE INFORMATION IN THIS BORDER HAS NOT BEEN AUDITED A TRADE DEBTORS B OBLIGATIONS UNDER FINANCE LEASES C ACCRUALS AND DEFERRED INCOME THE LEVEL OF TRADE DEBTORS REDUCED DRAMATICALLY IN DECEMBER 2001, WE PUT IN PLACE A FIVE-YEAR $40M 49.5M OF DEFERRED INCOME IS INCLUDED WITHIN THE DURING 2003.
AT THE END OF 2002, TRADE DEBTORS C. 22.3M FINANCE LEASE FACILITY IN RESPECT OF THE TOTAL HERE OF 74.3M, WHICH REPRESENTS THE DIFFERENCE PRINCIPALLY REPRESENTED AMOUNTS OWED BY THE CDC REACTIVATION OF OUR MANUFACTURING PLANT.
AT THE END BETWEEN INVOICES SUBMITTED TO THE CDC UNDER ITS TO ACAMBIS UNDER ITS 155 MILLION-DOSE SMALLPOX OF 2003,12.6M $22.5M WAS OWED UNDER THIS FACILITY, $428M C. 240M SMALLPOX VACCINE CONTRACT AND VACCINE CONTRACT THAT WERE PAID IN EARLY 2003.
ALL CAPITAL AMOUNTS RECORDED AS REVENUE IN THE PERIOD 2001 OBLIGATIONS UNDER THIS LEASE WILL BE DISCHARGED TO 2003.
WE EXPECT THIS AMOUNT WILL SUBSTANTIALLY IN THE PERIOD 2004 TO 2006.
